An SmPC, or Summary of Product Characteristics, is the official document that describes everything a healthcare professional needs to know about a medicine: what it treats, how to dose it, what side effects to watch for, and who should not take it. It is a legal document required for every medicine authorized for sale in the European Union, and it forms the core of a drug’s marketing authorization. If you’ve come across the term while reading about a medication, a clinical guideline, or a pharmaceutical regulation, this is the document being referenced.
What the SmPC Contains
Every SmPC follows a standardized structure so that doctors, pharmacists, and nurses can quickly find the information they need. The document covers the medicine’s name and formulation, its approved uses (called therapeutic indications), dosing instructions, contraindications (situations where the medicine should not be used), warnings, side effects, and pharmacological properties. It also includes details about shelf life, storage conditions, and the marketing authorization holder.
Because the format is consistent across all medicines in the EU, a pharmacist looking up a new cancer drug and a GP checking an antibiotic will find the same section headings in the same order. This predictability is deliberate. The European Medicines Agency (EMA) sets the template, and pharmaceutical companies must follow it when submitting their application for market approval.
Who the SmPC Is Written For
The SmPC is written specifically for healthcare professionals, not patients. The language is technical, the data is detailed, and the document assumes the reader has medical or pharmaceutical training. It is the most commonly used reference document for doctors in the EU when they need product-specific information about a medicine.
Patients receive a different document: the Patient Information Leaflet, or PIL. This is the folded paper insert you find inside a medicine box. The PIL draws its content from the SmPC but translates it into plain language, focusing on what a patient needs to know about taking the medicine safely. The SmPC, by contrast, includes clinical data, pharmacokinetic profiles, and prescribing nuances that would be meaningless to most patients but essential for the professionals managing their care.
Its Legal Weight
The SmPC is not just informational. It is a legal document, one of the mandatory components of the registration dossier that a pharmaceutical company submits to gain marketing authorization. No medicine can be sold in the EU without an approved SmPC. The document defines the officially sanctioned conditions of use, meaning that if a doctor prescribes a medicine outside the terms described in the SmPC, they are prescribing “off-label” and take on additional clinical and legal responsibility.
This legal status also means the SmPC is a living document. When new safety data emerges, when an additional use is approved, or when contraindications change, the SmPC must be updated to reflect the current state of evidence. These updates go through the same regulatory review process as the original approval.
How It Differs From the U.S. Equivalent
The United States does not use SmPCs. Instead, the FDA requires a Package Insert (also called the U.S. Prescribing Information, or USPI), which serves a similar purpose: providing healthcare professionals with the safety and effectiveness data needed to use a medicine appropriately. Despite covering the same general topics, the two documents are not interchangeable.
A study comparing FDA Package Inserts with EMA SmPCs found little harmonization between the two. The same information is organized differently, and even the terminology diverges. Where the EMA uses “therapeutic indications,” the FDA uses “indications and usage.” More significantly, the actual content can differ in ways that affect patient care. For example, one meningococcal vaccine was approved in the U.S. for people aged 2 months to 55 years, while the EMA’s SmPC set the age range from 2 years of age. A shingles vaccine’s SmPC listed active untreated tuberculosis as a contraindication, while the U.S. documents did not. These differences reflect independent regulatory evaluations of the same clinical data, and they can lead to different dosing schedules, age recommendations, and approved uses for the same product in different regions.
Where to Find an SmPC
For medicines that went through the EMA’s centralized authorization process, you can search for SmPCs directly on the EMA’s website using its medicines database. You enter the medicine’s name or active substance, and the search results include the full SmPC as a downloadable document. For medicines authorized through national procedures (approved by individual EU countries rather than centrally), you would check the national medicines register of the relevant country, such as the MHRA in the UK or the BfArM in Germany.
These databases are publicly accessible, so while the SmPC is written for professionals, anyone can read one. If you’re a patient trying to understand a specific medicine, the Patient Information Leaflet will usually be more useful. But if you want the complete, unfiltered regulatory record of what a medicine is approved to do and what risks have been identified, the SmPC is the primary source.
Known Limitations
Despite its central role, the SmPC is not without criticism. Healthcare professionals have noted that the documents can be difficult to interpret, even for trained readers. Research published in the International Journal of Environmental Research and Public Health found that doctors, nurses, and pharmacists have repeatedly called for a fresh approach to how SmPCs are written, arguing that some sections are ambiguous or open to conflicting interpretations. The same research raised concerns that SmPCs, while positioned as the official source of medicine information, may not always be fully reliable references for clinical decision-making, since they are initially drafted by pharmaceutical companies before regulatory review.
None of this diminishes the SmPC’s importance. It remains the foundational document for every medicine on the EU market, the starting point for prescribing decisions, and the legal benchmark against which a medicine’s use is measured. Understanding what it is and what it contains gives you a clearer picture of how medicines are regulated and how the information that guides your doctor’s decisions gets produced.